About Kodo LifeScience
Kodo LifeScience is a Healthcare company based in Valsad (India) founded in 2023. It offers plasmid DNA solutions and lentiviral vectors for Cell and Gene Therapy development. It operates on a B2B model in Healthcare and Agriculture sectors. Kodo LifeScience offers products and services including GMP Grade pDNA, GLP Grade pDNA, Lentiviral Vector Solutions, Packaging Plasmids, and Vector Production. Its focus areas include Biotechnology, Therapeutics, Cell and Gene Therapy and R&D Services. Its legal entity in India is Kodo Lifescience Pvt. Ltd (U21001GJ2023PTC143600). Its competitors include Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Quotient Sciences and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
Kodo LifeScience is a specialized organization in India focused on Cell and Gene Therapy, providing raw materials, process development, and GMP facilities. With RD expertise from IIT Madras, they deliver plasmid DNA solutions, lentiviral vectors, and consulting services. They support partners from proof of concept to commercialization through dedicated program management and quality assurance, ensuring operational excellence and innovation.
- Headquarters Valsad, India
- SectorsHealthcareAgriculture
- Email••••••••
- Website kodolifescience.com
- Social LinkedIn
- Legal Name Kodo Lifescience Pvt. Ltd.
- Date of Incorporation 04 Aug, 2023
- Jurisdiction Pardi, Gujarat, India
- Annual Revenue₹30,916
FY 2025
- Net Loss-₹1.04 Cr
FY 2025 · -33486% margin
- EBITDA-₹1.02 Cr
FY 2025 · -32901% margin
Associated legal entities of Kodo LifeScience
Kodo LifeScience operates through Kodo Lifescience Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Kodo Lifescience Private Limited CIN U21001GJ2023PTC143600 | Active | 04 Aug 2023 | Pardi, Gujarat | ₹0.0 Cr | – | 4 | View details |
Products & Services of Kodo LifeScience
Kodo LifeScience offers a comprehensive portfolio of products and services, including GMP Grade pDNA, GLP Grade pDNA, Lentiviral Vector Solutions, Packaging Plasmids, and Vector Production.
High-quality plasmid DNA for Cell and Gene Therapy manufacturing.
Plasmid DNA for research and development purposes.
Vectors for gene delivery in therapeutic applications.
Components for vector production in Cell Therapy.
Production of vectors for gene therapy support.
Assistance in developing cell-based therapies.
Optimization of therapy development processes.
End-to-end support for therapy manufacturing.
Expert advice on Cell and Gene Therapy strategies.
Board of directors of Kodo Lifescience Private Limited (Kodo LifeScience)
Kodo Lifescience Private Limited is the primary company behind Kodo LifeScience. The board of Kodo Lifescience Private Limited currently have 4 directors; the longest-serving is Maulesh Jayendrabhai Shah, appointed in 2023. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Maulesh Jayendrabhai Shah DIN 02727710 | Director | 04 Aug 2023 | 3 yrs 2 mo | Kodo Lifescience Private Limited |
| Siraj Jikar Saiyed DIN 01097575 | Director | 04 Aug 2023 | 3 yrs 2 mo | Kodo Lifescience Private Limited |
| Dimpalkumar Dhirajlal Shah DIN 06603044 | Director | 05 Sep 2024 | 2 yrs 1 mo | Kodo Lifescience Private Limited |
| Chintan Tarun Patel DIN 10728810 | Director | 05 Sep 2024 | 2 yrs 1 mo | Kodo Lifescience Private Limited |
Financials of Kodo LifeScience
Figures of Kodo Lifescience Private Limited, the primary company behind Kodo LifeScience, for FY 2025. Revenue was ₹30,916. Net loss was -₹1.04 Cr (-33486% margin). EBITDA was -₹1.02 Cr (-32901% margin).
- ₹30,916Revenue · FY 2025
- -₹1.04 CrNet loss · -33486% margin
- -₹1.02 CrEBITDA · -32901% margin
- ₹1.00 CrPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Kodo Lifescience Private Limited are on its company page.
Detailed financial statements for Kodo LifeScience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Kodo LifeScience
Kodo LifeScience has 8 listed competitors in our database, 6 of them funded. They include Suanfarma, Enzene Biosciences, Hybio Pharmaceutical, Nephron Pharmaceuticals and Quotient Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| suanfarma.com | 1993 | Madrid, Spain | – | – | Generics, nutraceuticals, and APIs are developed by Suanfarma. | |
| enzene.com | 2006 | Pune, India | $50M | 10 | Company specializing in development of Biosimilars | |
| hybio.com.cn | 1998 | Shenzhen, China | $15M | – | Polypeptide drugs and APIs are developed and manufactured. | |
| nephronpharm.com | 1937 | Florida, Puerto Rico | $625M | 1,578 | Sterile pharmaceutical products are manufactured and contract services are provided. | |
| quotientsciences.com | 1990 | Nottingham, United Kingdom | – | 369 | APIs and finished dosage forms are developed and manufactured. | |
| ambiopharm.com | 2006 | North Augusta, United States | $24M | 186 | CDMO and analytical services for peptide development are provided. | |
| kardigan.bio | 2023 | San Francisco, United States | $554M | – | Biotech company developing personalized medicines for cardiovascular diseases | |
| aiolosbio.com | 2023 | Boston, United States | $245M | – | Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions |
Detailed competitors of Kodo LifeScience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Kodo LifeScience (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kodo LifeScience
Kodo LifeScience was founded in 2023.
Kodo LifeScience is headquartered in Valsad, India. It is registered at Valsad, Gujarat, India.
The primary company behind Kodo LifeScience, Kodo Lifescience Private Limited, reported revenue of ₹30,916 for FY 2025.
Kodo LifeScience is a specialized organization in India focused on Cell and Gene Therapy, providing raw materials, process development, and GMP facilities. With RD expertise from IIT Madras, they deliver plasmid DNA solutions, lentiviral vectors, and consulting services. They support partners from proof of concept to commercialization through dedicated program management and quality assurance, ensuring operational excellence and innovation.
Kodo LifeScience's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
Kodo LifeScience offers GMP Grade pDNA, GLP Grade pDNA, Lentiviral Vector Solutions, Packaging Plasmids, and 5 more products and services.
Kodo LifeScience operates through Kodo Lifescience Private Limited.
The legal entities of Kodo LifeScience currently have 4 directors, including Dimpalkumar Dhirajlal Shah, Chintan Tarun Patel, Maulesh Jayendrabhai Shah and others.